Integrated Biopharma, Inc. INBP
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.80M | 10.11M | 11.28M | 12.69M | 14.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.80M | 10.11M | 11.28M | 12.69M | 14.18M |
| Cost of Revenue | 9.77M | 10.38M | 11.25M | 11.67M | 12.71M |
| Gross Profit | 28.00K | -276.00K | 29.00K | 1.02M | 1.47M |
| SG&A Expenses | 897.00K | 809.00K | 943.00K | 856.00K | 880.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.67M | 11.19M | 12.19M | 12.53M | 13.59M |
| Operating Income | -869.00K | -1.09M | -914.00K | 163.00K | 589.00K |
| Income Before Tax | -850.00K | -1.04M | -874.00K | 196.00K | 595.00K |
| Income Tax Expenses | 516.00K | -198.00K | -112.00K | 73.00K | 773.00K |
| Earnings from Continuing Operations | -1.37M | -837.00K | -762.00K | 123.00K | -178.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.37M | -837.00K | -762.00K | 123.00K | -178.00K |
| EBIT | -869.00K | -1.09M | -914.00K | 163.00K | 589.00K |
| EBITDA | -799.00K | -1.02M | -836.00K | 240.00K | 660.00K |
| EPS Basic | -0.04 | -0.03 | -0.02 | 0.00 | -0.01 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | 0.00 | 0.01 |
| EPS Diluted | -0.04 | -0.03 | -0.03 | 0.00 | -0.01 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | 0.00 | 0.01 |
| Average Basic Shares Outstanding | 31.06M | 31.06M | 31.06M | 31.06M | 30.61M |
| Average Diluted Shares Outstanding | 31.06M | 31.06M | 31.06M | 31.42M | 30.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |